| Ciclosporin |
0778/10.10.2007 г. |
Sandimmun Neoral, Oral solution, 100 mg/ml - 50 ml, -, Pack: 1 |
Novartis Pharma GmbH, Германия |
Novartis Pharma GmbH, Германия |
109.57 |
21.91 |
131.48 |
4% |
4.38 |
113.95 |
22.79 |
136.74 |
16% |
17.53 |
131.48 |
26.3 |
157.78 |
|
НСР-8235/22.02.2016 |
09.03.2016 |
09.03.2016 |
Неактивен |
3937 |
| Ciclosporin |
0778/10.10.2007 г. |
Sandimmun Neoral, Oral solution, 100 mg/ml - 50 ml, -, Pack: 1 |
Novartis Pharma GmbH, Германия |
Novartis Pharma GmbH, Германия |
109.57 |
21.91 |
131.48 |
4% |
4.38 |
113.95 |
22.79 |
136.74 |
16% |
17.53 |
131.48 |
26.3 |
157.78 |
|
НСР-8235/22.02.2016 |
09.03.2016 |
09.03.2016 |
Неактивен |
3937 |
| Ciclosporin |
0778/10.10.2007 г. |
Sandimmun Neoral, Oral solution, 5000, mg, Pack: 1 |
Novartis Pharma GmbH, Германия |
Novartis Pharma GmbH, Германия |
136.97 |
27.39 |
164.36 |
4% |
5.48 |
142.45 |
28.49 |
170.94 |
16% |
21.92 |
164.37 |
32.87 |
197.24 |
Отхвърля като неоснователна жалбата от Комисия по прозрачност с решение КП-269/15.05.2015 |
НСР-5823/12.03.2015 |
02.06.2015 |
02.06.2015 |
Неактивен |
3937 |
| Ciclosporin |
0778/10.10.2007 г. |
Sandimmun Neoral, Oral solution, 5000, mg, Pack: 1 |
Novartis Pharma GmbH, Германия |
Novartis Pharma GmbH, Германия |
160.69 |
32.14 |
192.83 |
4% |
6.43 |
167.12 |
33.42 |
200.54 |
16% |
25 |
192.12 |
38.42 |
230.54 |
|
КЦРР-920/04.07.2012 |
19.07.2012 |
19.07.2012 |
Неактивен |
3937 |
| Ciclosporin |
0778/10.10.2007 г. |
Sandimmun Neoral, Oral solution, 5000, mg, Pack: 1 |
Novartis Pharma GmbH, Германия |
Novartis Pharma GmbH, Германия |
172.72 |
34.54 |
207.26 |
6% |
10.36 |
183.08 |
36.62 |
219.7 |
18% |
30 |
213.08 |
42.62 |
255.7 |
|
КЦ-531/19.02.2009 |
13.03.2009 |
13.03.2009 |
Неактивен |
3937 |
| Octreotide |
0783/10.10.2007 г. |
SANDOSTATIN, Solution for injection, 0.1 mg/ml - 1 ml, mg, Pack: 5 |
Novartis Pharma GmbH, Германия |
Novartis Pharma GmbH, Germany |
13.1 |
2.62 |
15.72 |
6% |
0.79 |
13.89 |
2.78 |
16.67 |
18% |
2.36 |
16.25 |
3.25 |
19.5 |
|
КЦРР-2120/28.01.2013 г; НСР-12218/03.04.2017 |
18.04.2017 |
02.05.2017 |
Активен |
1624 |
| Octreotide |
20000367 |
Sandostatin LAR, Powder and solvent for suspension for injection, 30, mg, Pack: 1 |
Novartis Pharma GmbH, Германия |
Novartis Pharma GmbH, Германия |
814.41 |
162.88 |
977.29 |
4% |
10 |
824.41 |
164.88 |
989.29 |
16% |
25 |
849.41 |
169.88 |
1019.29 |
Промяна на обстоятелствата НСР-16146/13.07.2018 |
НСР-4758/ 02.10.2014; КП-64/31.08.2017 и НСР-12930/08.06.2017; НСР-15709/21.05.2018 (предварително изпълнение); НСР-19192/12.07.2019; НСР-20904/27.02.2020 |
13.03.2020 |
02.04.2020 |
Активен |
3243 |
| Octreotide |
20000367 |
Sandostatin LAR, Powder and solvent for suspension for injection, 30, mg, Pack: 1 |
Novartis Pharma GmbH, Германия |
Novartis Pharma GmbH,Roonstrasse 25, 90429 Nurnberg, Германия |
912.65 |
182.53 |
1095.18 |
4% |
10 |
922.65 |
184.53 |
1107.18 |
16% |
25 |
947.65 |
189.53 |
1137.18 |
Промяна на обстоятелствата НСР-16146/13.07.2018. |
НСР-4758/ 02.10.2014; КП-64/31.08.2017 и НСР-12930/08.06.2017; НСР-15709/21.05.2018 (предварително изпълнение); НСР-19192/12.07.2019 |
27.07.2019 |
02.08.2019 |
Неактивен |
3243 |
| Octreotide |
20000366 |
Sandostatin LAR, Powder and solvent for suspension for injection, 20, mg, Pack: 1 |
Novartis Pharma GmbH, Германия |
Novartis Pharma GmbH, Германия |
542.94 |
108.59 |
651.53 |
4% |
10 |
552.94 |
110.59 |
663.53 |
16% |
25 |
577.94 |
115.59 |
693.53 |
Промяна на обстоятелствата НСР-16145/13.07.2018. |
НСР-6491/18.06.2015; КП-162/29.11.2017 и НСР-13878/25.09.2017; НСР-16928/04.10.2018; НСР-18971/13.06.2019; НСР-20732/30.01.2020 |
14.02.2020 |
02.03.2020 |
Активен |
2230 |
| Octreotide |
20000366 |
Sandostatin LAR, Powder and solvent for suspension for injection, 20, mg, Pack: 1 |
Novartis Pharma GmbH, Германия |
Novartis Pharma GmbH, Germany |
608.44 |
121.69 |
730.13 |
4% |
10 |
618.44 |
123.69 |
742.13 |
16% |
25 |
643.44 |
128.69 |
772.13 |
Промяна на обстоятелствата НСР-16145/13.07.2018. |
НСР-6491/18.06.2015; КП-162/29.11.2017 и НСР-13878/25.09.2017; НСР-16928/04.10.2018; НСР-18971/13.06.2019 |
28.06.2019 |
02.07.2019 |
Неактивен |
2230 |
| Octreotide |
20000367 |
Sandostatin LAR, Powder and solvent for suspension for injection, 30, mg, Pack: 1 |
Novartis Pharma GmbH, Германия |
Novartis Pharma GmbH,Roonstrasse 25, 90429 Nurnberg, Германия |
912.65 |
182.53 |
1095.18 |
4% |
10 |
922.65 |
184.53 |
1107.18 |
16% |
25 |
947.65 |
189.53 |
1137.18 |
Промяна на обстоятелствата НСР-16146/13.07.2018. |
НСР-4758/ 02.10.2014; КП-64/31.08.2017 и НСР-12930/08.06.2017; НСР-15709/21.05.2018 (предварително изпълнение); НСР-19192/12.07.2019 |
27.07.2019 |
02.08.2019 |
Неактивен |
3243 |
| Octreotide |
20000366 |
Sandostatin LAR, Powder and solvent for suspension for injection, 20, mg, Pack: 1 |
Novartis Pharma GmbH, Германия |
Novartis Pharma GmbH, Germany |
608.44 |
121.69 |
730.13 |
4% |
10 |
618.44 |
123.69 |
742.13 |
16% |
25 |
643.44 |
128.69 |
772.13 |
Промяна на обстоятелствата НСР-16145/13.07.2018. |
НСР-6491/18.06.2015; КП-162/29.11.2017 и НСР-13878/25.09.2017; НСР-16928/04.10.2018; НСР-18971/13.06.2019 |
28.06.2019 |
02.07.2019 |
Неактивен |
2230 |
| Octreotide |
20000367 |
Sandostatin LAR, Powder and solvent for suspension for injection, 30, mg, Pack: 1 |
Novartis Pharma GmbH, Германия |
Novartis Pharma GmbH,Roonstrasse 25, 90429 Nurnberg, Германия |
1019.16 |
203.83 |
1222.99 |
4% |
10 |
1029.16 |
205.83 |
1234.99 |
16% |
25 |
1054.16 |
210.83 |
1264.99 |
Промяна на обстоятелствата НСР-16146/13.07.2018. |
НСР-4758/ 02.10.2014; КП-64/31.08.2017 и НСР-12930/08.06.2017; НСР-15709/21.05.2018 (предварително изпълнение) |
21.05.2018 |
02.08.2018 |
Неактивен |
3243 |
| Octreotide |
20000366 |
Sandostatin LAR, Powder and solvent for suspension for injection, 20, mg, Pack: 1 |
Novartis Pharma GmbH, Германия |
Novartis Pharma GmbH, Germany |
679.44 |
135.89 |
815.33 |
4% |
10 |
689.44 |
137.89 |
827.33 |
16% |
25 |
714.44 |
142.89 |
857.33 |
Промяна на обстоятелствата НСР-16145/13.07.2018. |
НСР-6491/18.06.2015; КП-162/29.11.2017 и НСР-13878/25.09.2017; НСР-16928/04.10.2018 |
19.10.2018 |
02.11.2018 |
Неактивен |
2230 |
| Octreotide |
20000366 |
Sandostatin LAR, Powder and solvent for suspension for injection, 20, mg, Pack: 1 |
Novartis Pharma GmbH, Германия |
Novartis Pharma GmbH, Germany |
842.02 |
168.4 |
1010.42 |
4% |
10 |
852.02 |
170.4 |
1022.42 |
16% |
25 |
877.02 |
175.4 |
1052.42 |
Промяна на обстоятелствата НСР-16145/13.07.2018. |
НСР-6491/18.06.2015; КП-162/29.11.2017 и НСР-13878/25.09.2017 |
02.02.2018 |
02.08.2018 |
Неактивен |
2230 |
| Octreotide |
II-11112/ 04.11.2010 |
Sandostatin LAR, Powder and solvent for suspension for injection, 30, mg, Pack: 1 |
Novartis Pharma GmbH, Германия |
Novartis Pharma GmbH,Roonstrasse 25, 90429 Nurnberg, Германия |
1019.16 |
203.83 |
1222.99 |
4% |
10 |
1029.16 |
205.83 |
1234.99 |
16% |
25 |
1054.16 |
210.83 |
1264.99 |
|
НСР-4758/ 02.10.2014; КП-64/31.08.2017 и НСР-12930/08.06.2017; НСР-15709/21.05.2018 (предварително изпълнение) |
21.05.2018 |
02.07.2018 |
Неактивен |
3243 |
| Octreotide |
0785/10.10.2007 г. |
Sandostatin LAR, Powder and solvent for suspension for injection, 20, mg, Pack: 1 |
Novartis Pharma GmbH, Германия |
Novartis Pharma GmbH, Germany |
842.02 |
168.4 |
1010.42 |
4% |
10 |
852.02 |
170.4 |
1022.42 |
16% |
25 |
877.02 |
175.4 |
1052.42 |
|
НСР-6491/18.06.2015; КП-162/29.11.2017 и НСР-13878/25.09.2017 |
02.02.2018 |
02.02.2018 |
Неактивен |
2230 |
| Octreotide |
II-11112/ 04.11.2010 |
Sandostatin LAR, Powder and solvent for suspension for injection, 30, mg, Pack: 1 |
Novartis Pharma GmbH, Германия |
Novartis Pharma GmbH,Roonstrasse 25, 90429 Nurnberg, Германия |
1019.16 |
203.83 |
1222.99 |
4% |
10 |
1029.16 |
205.83 |
1234.99 |
16% |
25 |
1054.16 |
210.83 |
1264.99 |
|
НСР-4758/ 02.10.2014; КП-64/31.08.2017 и НСР-12930/08.06.2017; НСР-15709/21.05.2018 (предварително изпълнение)* |
21.05.2018 |
02.06.2018 |
Неактивен |
3243 |
| Octreotide |
II-11112/ 04.11.2010 |
Sandostatin LAR, Powder and solvent for suspension for injection, 30, mg, Pack: 1 |
Novartis Pharma GmbH, Германия |
Novartis Pharma GmbH,Roonstrasse 25, 90429 Nurnberg, Германия |
1263.04 |
252.61 |
1515.65 |
4% |
10 |
1273.04 |
254.61 |
1527.65 |
16% |
25 |
1298.04 |
259.61 |
1557.65 |
|
НСР-4758/ 02.10.2014; КП-64/31.08.2017 и НСР-12930/08.06.2017 |
02.10.2017 |
02.10.2017 |
Неактивен |
3243 |
| Octreotide |
0785/10.10.2007 г. |
Sandostatin LAR, Powder and solvent for suspension for injection, 20, mg, Pack: 1 |
Novartis Pharma GmbH, Германия |
Novartis Pharma GmbH, Germany |
1156.52 |
231.3 |
1387.82 |
4% |
10 |
1166.52 |
233.3 |
1399.82 |
16% |
25 |
1191.52 |
238.3 |
1429.82 |
|
НСР-6491/18.06.2015 |
04.07.2015 |
04.07.2015 |
Неактивен |
2230 |
| Octreotide |
II-11112/ 04.11.2010 |
Sandostatin LAR, Powder and solvent for suspension for injection, 30, mg, Pack: 1 |
Novartis Pharma GmbH, Германия |
Novartis Pharma GmbH,Roonstrasse 25, 90429 Nurnberg, Германия |
1734.78 |
346.96 |
2081.74 |
4% |
10 |
1744.78 |
348.96 |
2093.74 |
16% |
25 |
1769.78 |
353.96 |
2123.74 |
|
НСР-4758/ 02.10.2014 |
16.10.2014 |
16.10.2014 |
Неактивен |
3243 |
| Octreotide |
0785/10.10.2007 г. |
Sandostatin LAR, Powder and solvent for suspension for injection, 20, mg, Pack: 1 |
Novartis Pharma GmbH, Германия |
Novartis Pharma GmbH, Germany |
1504.5 |
300.9 |
1805.4 |
4% |
10 |
1514.5 |
302.9 |
1817.4 |
16% |
25 |
1539.5 |
307.9 |
1847.4 |
|
НСР-1597/01.11.2013 |
19.11.2013 |
19.11.2013 |
Неактивен |
2230 |
| Octreotide |
0785/10.10.2007 г. |
Sandostatin LAR, Powder and solvent for suspension for injection, 20, mg, Pack: 1 |
Novartis Pharma GmbH, Германия |
Novartis Pharma GmbH, Germany |
1507.81 |
301.56 |
1809.37 |
4% |
10 |
1517.81 |
303.56 |
1821.37 |
16% |
25 |
1542.81 |
308.56 |
1851.37 |
|
КЦРР-2121/28.01.2013 г |
25.02.2013 |
25.02.2013 |
Неактивен |
2230 |
| Octreotide |
II-11112/ 04.11.2010 |
Sandostatin LAR, Powder and solvent for suspension for injection, 30, mg, Pack: 1 |
Novartis Pharma GmbH, Германия |
Novartis Pharma GmbH,Roonstrasse 25, 90429 Nurnberg,Германия |
1983.58 |
396.72 |
2380.3 |
4% |
10 |
1993.58 |
398.72 |
2392.3 |
16% |
25 |
2018.58 |
403.72 |
2422.3 |
|
КЦРР-2185/06.02.2013 г |
25.02.2013 |
25.02.2013 |
Неактивен |
3243 |
| Octreotide |
II-11112/ 04.11.2010 |
Sandostatin LAR, Powder and solvent for suspension for injection, 30, mg, Pack: 1 |
Novartis Pharma GmbH, Германия |
Novartis Pharma GmbH,Roonstrasse 25, 90429 Nurnberg,Германия |
2003.63 |
400.73 |
2404.36 |
4% |
10 |
2013.63 |
402.73 |
2416.36 |
16% |
25 |
2038.63 |
407.73 |
2446.36 |
корекц. КЦPP-424/19.04.2012 |
КЦРР-307/15.03.2012 |
03.04.2012 |
03.04.2012 |
Неактивен |
3243 |